Stock Evaluator: Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics, Inc. TNGX

$21.89 -0.22 -1.00%
November 18, 2026 4:00:00 PM EST November 10, 2021 Volume: 2,746,141
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics TNGX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $3,709.4 $213.9 64%
Shares Out (Mil) 173.9 55.4 73%
Institutional Ownership 99.1% 93.3% 84%
Float (Mil) 143.1 40.6 67%
Beta 1.22 0.98 71%
Avg Daily Volume (000s) 2,904 597 85%
Price Change
(52-week)
174.3% 40.9% 98%
Growth TNGX Industry
Median
Percentile
(All Stocks)
Sales (5yr) 52.0% 13.2% 96%
Net Income (5yr) (14.3%) (10.7%) 26%
EPS (5yr) 11.7% 15.5% 50
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 16.8% (15.7%) 76%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 13 13 13
Current EPS ($0.419) ($1.472) ($1.793)
Month Ago EPS ($0.373) ($1.397) ($1.661)
# Rev Up 0 1 0
# Rev Down 1 1 1
Three Months Ago EPS ($0.367) ($1.380) ($1.628)
Year/Year Chg 6.6% 68.2% 137.5%
Financials TNGX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $39 na
Net Income (TTM) (Mil) ($208) ($44) 6%
EPS (TTM) ($1.378) ($1.400) 17%
Operating Cash Flow (TTM) (Mil) ($150) ($34) 5%
Net Cash Flow (TTM) (Mil) $28 $-0 66%
Long-Term Debt (Q1) (Mil) $28 $4 34%
Enterprise Value (Q1) (Mil) $2,907 $135 54%
Valuation TNGX Industry
Median
Percentile
(All Stocks)
P/B 3.78 1.97 75%
P/E na 17.6 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.8 na
Ratios TNGX Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.9% na
Net Margin na (50.8%) na
ROA (33.5%) (47.5%) 15%
ROE (36.5%) (51.9%) 18%
Liabilities to Assets 5.2% 29.7% 2%
F-Score 3 3 18%

Tango Therapeutics, Inc. did not pass any screens on 11/18/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors